Event-free survival analysis
| Variable . | Class/cutoff . | n (%) . | Univariate analysis* . | Multivariate analysis† . | ||
|---|---|---|---|---|---|---|
| Hazard ratio of event risk . | P . | Hazard ratio of event risk . | P . | |||
| Bcl2‡ | IHC score > 0 | 53 (39.8) | 1.22 (0.726-2.034) | .46 | ||
| EBV‡ | IHC score > 0 | 29 (20.4) | 0.668 (0.338-1.319) | .24 | ||
| PD1 | IHC score > 1 | 8 (18.2) | 0.627 (0.179-2.193) | .46 | ||
| CD57 | IHC score > 1 | 42 (35.3) | 1.42 (0.81-2.493) | .22 | ||
| FOXP3 | IHC score > 1 | 97 (73.5) | 0.555 (0.32-0.966) | .037 | ||
| Tryptase | IHC score > 1 | 75 (54) | 0.892 (0.537-1.482) | .66 | ||
| TIA-1 | IHC score > 2 | 34 (24.5) | 1.16 (0.654-2.063) | .61 | ||
| Granzyme B | IHC score > 1 | 40 (36.4) | 1.25 (0.707-2.201) | .45 | ||
| PS100 | IHC score > 1 | 77 (53.8) | 0.808 (0.49-1.33) | .4 | ||
| TopoIIa‡ | IHC score > 1 | 66 (49.3) | 1.75 (1.048-2.918) | .032 | ||
| BFAR‡ | IHC score > 1 | 84 (70.6) | 0.756 (0.416-1.372) | .36 | ||
| Smad4 | IHC score > 0 | 20 (29.4) | 0.742 (0.345-1.597) | .45 | ||
| Bcl11A | IHC score > 1 | 68 (53.1) | 0.216 (0.122-0.38) | 1.10 × 10−7 | 0.206 (0.107-0.394) | 1.80 × 10−6 |
| CD20 | IHC score > 1 | 76 (53.9) | 0.532 (0.318-0.89) | .016 | ||
| CD8 | IHC score >1 | 54 (45.4) | 0.792 (0.451-1.39) | .42 | ||
| Stat1 | IHC score > 1 | 33 (42.9) | 0.746 (0.378-1.472) | .4 | ||
| BDCA2 | IHC score > 1 | 24 (35.3) | 1.31 (0.625-2.745) | .47 | ||
| Age | ≥ 45 y | 21 (14.9) | 1.46 (0.758-2.808) | .26 | ||
| Sex | Female | 64 (44.8) | 0.71 (0.426-1.185) | .19 | ||
| Ann Arbor | III-IV | 59 (41.3) | 1.19 (0.719-1.976) | .5 | ||
| B symptom | Present | 47 (40.5) | 1.57 (0.901-2.738) | .11 | ||
| Bulky tumor | Present | 47 (40.5) | 2.35 (1.348-4.104) | .003 | ||
| Extranodal disease | Present | 19 (16.4) | 1.2 (0.56-2.589) | .63 | ||
| No. of nodal sites | ≥ 3 | 61 (48) | 1.18 (0.677-2.054) | .56 | ||
| Inguinal involvement | Present | 9 (9.4) | 1.78 (0.69-4.594) | .23 | ||
| ESR | ≥ 50 | 59 (48.4) | 0.747 (0.428-1.302) | .3 | ||
| Hemoglobin | ≥ 10.5 g/dL | 105 (78.4) | 0.783 (0.428-1.432) | .43 | ||
| White cell count | > 15 × 109/L | 27 (19.9) | 1.98 (1.107-3.527) | .021 | 1.8 (0.912-3.559) | .09 |
| Lymphocyte count | ≥ 0.6 × 109/L or ≥ 8% | 103 (82.4) | 0.886 (0.455-1.725) | .72 | ||
| Albumin level | ≥ 40 g/L | 47 (45.6) | 0.337 (0.169-0.668) | .002 | ||
| Variable . | Class/cutoff . | n (%) . | Univariate analysis* . | Multivariate analysis† . | ||
|---|---|---|---|---|---|---|
| Hazard ratio of event risk . | P . | Hazard ratio of event risk . | P . | |||
| Bcl2‡ | IHC score > 0 | 53 (39.8) | 1.22 (0.726-2.034) | .46 | ||
| EBV‡ | IHC score > 0 | 29 (20.4) | 0.668 (0.338-1.319) | .24 | ||
| PD1 | IHC score > 1 | 8 (18.2) | 0.627 (0.179-2.193) | .46 | ||
| CD57 | IHC score > 1 | 42 (35.3) | 1.42 (0.81-2.493) | .22 | ||
| FOXP3 | IHC score > 1 | 97 (73.5) | 0.555 (0.32-0.966) | .037 | ||
| Tryptase | IHC score > 1 | 75 (54) | 0.892 (0.537-1.482) | .66 | ||
| TIA-1 | IHC score > 2 | 34 (24.5) | 1.16 (0.654-2.063) | .61 | ||
| Granzyme B | IHC score > 1 | 40 (36.4) | 1.25 (0.707-2.201) | .45 | ||
| PS100 | IHC score > 1 | 77 (53.8) | 0.808 (0.49-1.33) | .4 | ||
| TopoIIa‡ | IHC score > 1 | 66 (49.3) | 1.75 (1.048-2.918) | .032 | ||
| BFAR‡ | IHC score > 1 | 84 (70.6) | 0.756 (0.416-1.372) | .36 | ||
| Smad4 | IHC score > 0 | 20 (29.4) | 0.742 (0.345-1.597) | .45 | ||
| Bcl11A | IHC score > 1 | 68 (53.1) | 0.216 (0.122-0.38) | 1.10 × 10−7 | 0.206 (0.107-0.394) | 1.80 × 10−6 |
| CD20 | IHC score > 1 | 76 (53.9) | 0.532 (0.318-0.89) | .016 | ||
| CD8 | IHC score >1 | 54 (45.4) | 0.792 (0.451-1.39) | .42 | ||
| Stat1 | IHC score > 1 | 33 (42.9) | 0.746 (0.378-1.472) | .4 | ||
| BDCA2 | IHC score > 1 | 24 (35.3) | 1.31 (0.625-2.745) | .47 | ||
| Age | ≥ 45 y | 21 (14.9) | 1.46 (0.758-2.808) | .26 | ||
| Sex | Female | 64 (44.8) | 0.71 (0.426-1.185) | .19 | ||
| Ann Arbor | III-IV | 59 (41.3) | 1.19 (0.719-1.976) | .5 | ||
| B symptom | Present | 47 (40.5) | 1.57 (0.901-2.738) | .11 | ||
| Bulky tumor | Present | 47 (40.5) | 2.35 (1.348-4.104) | .003 | ||
| Extranodal disease | Present | 19 (16.4) | 1.2 (0.56-2.589) | .63 | ||
| No. of nodal sites | ≥ 3 | 61 (48) | 1.18 (0.677-2.054) | .56 | ||
| Inguinal involvement | Present | 9 (9.4) | 1.78 (0.69-4.594) | .23 | ||
| ESR | ≥ 50 | 59 (48.4) | 0.747 (0.428-1.302) | .3 | ||
| Hemoglobin | ≥ 10.5 g/dL | 105 (78.4) | 0.783 (0.428-1.432) | .43 | ||
| White cell count | > 15 × 109/L | 27 (19.9) | 1.98 (1.107-3.527) | .021 | 1.8 (0.912-3.559) | .09 |
| Lymphocyte count | ≥ 0.6 × 109/L or ≥ 8% | 103 (82.4) | 0.886 (0.455-1.725) | .72 | ||
| Albumin level | ≥ 40 g/L | 47 (45.6) | 0.337 (0.169-0.668) | .002 | ||
Univariate Cox proportional hazards regression model.
Cox proportional hazards regression model after backward stepwise variables selection procedure.
Bcl2, EBV, Topoisomerase-2, and BFAR immunostainings were analyzed on Reed-Sternberg cells, whereas the results mentioned for all other antibodies were analyzed on reactive cells.